10:32 AM
 | 
Oct 12, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA approves Leadiant therapy for ADA-SCID

Leadiant Biosciences Inc. said FDA approved Revcovi elapegademase-lvlr (EZN-2279) to treat pediatric and adult patients with adenosine deaminase severe combined immunodeficiency.

Approval of the pegylated recombinant adenosine deaminase enzyme replacement therapy is based on two Phase III trials in the U.S....

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >